Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms.

作者：Savanah D Gisriel, F. Aakash, John M. Bennett, R. Hasserjian, S. Loghavi, A. Dezern, V. Santini, M. Savona, Andrew M. Brunner, R. Buckstein, Andrew H. Wei, M. D. della Porta, R. Komrokji, U. Borate, M. Sekeres, U. Platzbecker, P. Fenaux, G. Roboz, A. A. van de Loosdrecht, A. Zeidan, Mina L. Xu · 发表于：Archives of Pathology & Laboratory Medicine · 年份：2025 · DOI：10.5858/arpa.2024-0322-ra · 被引用次数：3 · 研究领域：Medicine

CONTEXT.— Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. OBJECTIVE.— To propose a standardized approach to MDS evaluation in bone marrow specimens by (1) enhancing interinstitutional and intrainstitutional collaborations and clinical decision-making among hematopathologists and clinical hematologists and (2) allowing for efficient data extraction for clinical trials, institutional databases, and registry templates. This suggested approach is summarized in a modifiable, user-friendly template for hematopathologists to reference as they examine bone marrows (in the Supplemental Digital Content). DATA SOURCES.— We built upon the bone marrow template reporting guideline outlined by the College of American Pathologists Pathology and Laboratory Quality Center for Evidence-Based Guidelines and gathered expert insight from hematopathologists and hematologists-oncologists who specialize in MDS. CONCLUSIONS.— This proposed approach to MDS evaluation in the bone marrow standardizes reporting, which enhances communication among health care professionals and allows for efficient data extraction.